{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:10Z","timestamp":1789609090248,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Donor specific antibodies (DSAs) can be responsible for graft failure (GF) in the setting of mismatched hematopoietic stem cell transplantation (HSCT). The aim of our study is to report the experience of the Madrid Group of Hematopoietic Transplant (GMTH) in patients with DSAs undergoing haplo-HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients undergoing haplo-HSCT in centers from the GMTH from 2012 to 2020 were included in the study. DSAs were analyzed with a solid-phase single-antigen immunoassay; monitoring was performed during desensitization on days -14, -7, 0 and in a weekly basis until neutrophil engraftment. Desensitization strategies varied depending on center experience, immunofluorescence intensity, complement fixation and type of antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a total of 20 haplo-HSCT in 19 patients performed with DSAs in 5 centers. 10 (53%) patients presented anti-HLA class I DSAs (6 of them with &amp;gt; 5000 mean fluorescence intensity (MFI)), 4 (21%) presented anti-HLA class II (1 with &amp;gt; 5000 MFI) and 5 (26%) presented both anti-HLA class I and II (5 with &amp;gt; 5000 MFI). 90% of patients received at least two treatments as desensitization strategy and all experienced a decrease of MFI after desensitization (mean reduction 74%). Only one patient who developed progressive increase of MFI after infusion developed GF. Desensitization treatments used included rituximab, immunoglobulins, therapeutic plasma exchange, incompatible platelets, buffy coat and immunosuppressors. Seventeen (90%) patients achieved neutrophil engraftment; one patient died before engraftment because of infection and one patient with class I DSAs developed primary GF despite an intensive desensitization. After a median follow-up of 10 months, OS and EFS were 60% and 58%, respectively, cumulative incidence of relapse was 5% and NRM was 32%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite the optimal strategy of DSAs desensitization remains unclear, the use of desensitization treatment guided by DSAs intensity kinetics constitute an effective approach with high rates of engraftment for patients with DSAs in need for an haplo-HSCT lacking an alternative suitable donor.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.674658","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T05:37:18Z","timestamp":1621402638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant"],"prefix":"10.3389","volume":"12","author":[{"given":"Rebeca","family":"Bail\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sol\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"S\u00e1nchez-Vadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Alenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem","family":"Humala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabelle","family":"Chinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Balas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arzuaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pradillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillen","family":"Oarbeascoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"B1","unstructured":"Cibmtr Annual Report.2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2009-09-244525","article-title":"The Detection of Donor-Directed, HLA-Specific Alloantibodies in Recipients of Unrelated Hematopoietic Cell Transplantation is Predictive of Graft Failure","volume":"115","author":"Spellman","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200204270-00016","article-title":"Positive Serum Crossmatch as Predictor for Graft Failure in HLA-mismatched Allogeneic Blood Stem Cell Transplantation","volume":"73","author":"Ottinger","year":"2002","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable Engraftment of Major Histocompatibility Complex-Incompatible Cells After Nonmyeloablative Conditioning With Fludarabine, Low-Dose Total Body Irradiation, and Posttransplantation Cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"Hla-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362111","article-title":"Donor-Specific Anti-HLA Abs and Graft Failure in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation","volume":"118","author":"Ciurea","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249219","article-title":"The Impact of Anti-HLA Antibodies on Unrelated Cord Blood Transplantations","volume":"116","author":"Takanashi","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.177","article-title":"Early Peripheral Blood and T-cell Chimerism Dynamics After Umbilical Cord Blood Transplantation Supported With Haploidentical Cells","volume":"49","author":"Kwon","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355263","article-title":"Donor-Specific anti-HLA Antibodies Predict Outcome in Double Umbilical Cord Blood Transplantation","volume":"118","author":"Cutler","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.645","article-title":"HLA Donor-Specific Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation: Challenges and Opportunities","volume":"2017","author":"Gladstone","year":"2017","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (Ebmt) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-Hla Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00570","article-title":"Detection of HLA Antibodies in Organ Transplant Recipients \u2013 Triumphs and Challenges of the Solid Phase Bead Assay","volume":"7","author":"Tait","year":"2016","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-Binding Donor-Specific Anti-Hla Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and Prevention of Graft Failure in Patients With Preexisting Donor-Specific HLA Antibodies Undergoing Unmanipulated Haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.331","article-title":"Donor HLA-specific Abs: to BMT or Not to BMT","volume":"50","author":"Leffell","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4025073","article-title":"Donor Specific Anti-Hla Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation","volume":"2016","author":"Kongtim","year":"2016","journal-title":"Adv Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (Bmt Ctn)","volume":"21","author":"Howard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and Refinement of the Disease Risk Index for Allogeneic Stem Cell Transplantation: A Study From the CIBMTR","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"JCO"},{"key":"B22","article-title":"A Comparison of Fluorescent in Situ Hybridization and Multiplex Short Tandem Repeat Polymerase Chain Reaction for Quantifying Chimerism After Stem Cell Transplantation","volume":"90","author":"Bu\u00f1o","year":"2005","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: A Report From the Mount Sinai Acute Gvhd International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern Approaches to HLA-Haploidentical Blood or Marrow Transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1796621","article-title":"Evolution of the Role of Haploidentical Stem Cell Transplantation: Past, Present, and Future","volume":"13","author":"Kwon","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.239","article-title":"Graft Failure in the Modern Era of Allogeneic Hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0722-y","article-title":"Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor","volume":"55","author":"Deteix","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.006","article-title":"Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome (VOD\/SOS) After Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplantation Cyclophosphamide","volume":"26","author":"G\u00f3mez-Centuri\u00f3n","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.130","article-title":"Revised Diagnosis and Severity Criteria for Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease in Adult Patients: A New Classification From the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide Using Non\u2013First-Degree Related Donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007535","article-title":"Double Unrelated Umbilical Cord Blood vs HLA-Haploidentical Bone Marrow Transplantation: The BMT CTN 1101 Trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective Study of Nonmyeloablative, HLA-Mismatched Unrelated BMT With High-Dose Posttransplantation Cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.14302\/issn.2372-6601.jhor-18-1988","article-title":"Successful Allogeneic Hematopoietic Stem Cell Transplantation From A 5\/10 Mismatched Unrelated Donor in A Patient With Donor-Specific Anti-HLA Antibodies","volume":"3","author":"Moreno","year":"2018","journal-title":"JHOR"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.674658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T05:37:22Z","timestamp":1621402642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.674658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2021.674658"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.674658","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"article-number":"674658"}}